SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ZymeTx, Inc. - ZMTX new biotech company -- Ignore unavailable to you. Want to Upgrade?

To: Mike C2 who wrote (72)1/21/1999 12:22:00 PM
From: Henry Volquardsen  Respond to of 88
 
Mike,

That is what I understand the value is. The test will allow the doctor to better target treatment and avoid prescribing anti biotics when they are not appropriate. HMOs are a target for cost savings.

Henry



To: Mike C2 who wrote (72)1/21/1999 12:23:00 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 88
 
Nice segment yesterday afternoon (PST) with the CEO. Mostly hype until Glaxo and Roche get hot with therapeutics, but nice segment.



To: Mike C2 who wrote (72)1/23/1999 1:10:00 AM
From: Abe the babe  Respond to of 88
 
Mike, I think the value of the test may be more in relation to the elderly and the suscptible people being exposed to the risk of infection from contact with their health care provider..maybe it will be important to screen workers in hospitals and nursing homes, etc..and maybe it can be used by HMO's to avoid overprescribing antibiotics.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News